MAY 29, 2014 7:30 AM PDT

Identification of predictive biomarkers from high throughput drug combination screening data

Speaker
  • Director, Translational Medicine, Thermo-Fisher Scientific
    Biography
      With Thermo Fisher Scientific, Dr. Bowden leads Pharma Client Services to provide custom bioinformatics solutions for oncology drug development and research. This group develops complete solutions from target discovery and validation, predictive biomarkers of response and drug combination synergies, to clinical testing hypotheses   Dr. Bowden has more than 18 years of research and leadership experience in cancer biology and drug development in both academic and industry settings. She has served as an Assistant Professor at Georgetown University. While in industry, Dr. Bowden led multiple preclinical projects and strategy area teams supporting the development of various types of biologic including antibodies, multispecifics and antibody-drug conjugates. She holds a PhD in Biochemistry from University of Bristol. 

    Abstract

    One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding and overcoming tumor heterogeneity as well as inherent or emerging resistance are areas of significant ongoing research in both clinical and preclinical settings. Systematic approaches to support combination therapy clinical trial design are critical. Zalicus Inc. and Life Technologies have collaborated to develop a joint service offering that supports rationale design of cell line panels to inform and address the relevant genomic aberrations in disease subsequently enabling the identification of (1) potentially synergistic therapy combinations, (2) biomarkers of synergy, and (3) identification of potential clinical populations for hypothesis testing. During this segment, Dr. Bowden will discuss technical aspects of combination screening and biomarker discovery, major considerations required for success, provide examples of results, and offer potential impacts of this innovative service offering.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    Loading Comments...
    Show Resources